8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report

(Date of earliest event reported)

December 7, 2019

MARINUS PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware	001-36576	20-0198082
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

5 Radnor Corporate Center, Suite 500 100 Matsonford Rd, Radnor, PA	19087
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code:  (484) 801-4670

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Title of Each Class	Trading Symbol(s)	Name of Each Exchange on Which Registered
Common Stock, par value $0.001 per share	MRNS	Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x

Item 8.01. Other Events.

On December 7, 2019, Marinus Pharmaceuticals, Inc. (the “Company”) issued a press release announcing additional data from a Phase 2 trial with ganaxolone in refractory status epilepticus to be presented at the American Epilepsy Society Annual Meeting. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and a copy of the slides that accompany this presentation is filed as Exhibit 99.2 to this Current Report on Form 8-K and are incorporated by reference in this Item 8.01 as though fully set forth herein.

On December 9, 2019, the Company issued a press release announcing updates to its orphan seizure program including planned clinical program in tuberous sclerosis complex. A copy of the press release is filed as Exhibit 99.3 to this Current Report on Form 8-K and is incorporated by reference in this Item 8.01 as though fully set forth herein.

Item 9.01. Financial Statements and Exhibits.

Exhibit No.	Exhibit Description
99.1	Press Release dated December 7, 2019
99.2	Slide Presentation at American Epilepsy Society Annual Meeting on December 9, 2019 at 7:15 a.m. ET
99.3	Press Release dated December 9, 2019

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MARINUS PHARMACEUTICALS, INC.
By:	/s/ Edward Smith
	Edward Smith,
	Vice President, Chief Financial Officer,
	Secretary and Treasurer

Date:  December 9, 2019

3

EX-99.1

Exhibit 99.1

 

Marinus Presents Additional Data from Ganaxolone Phase 2 Trial in Refractory Status Epilepticus at the American Epilepsy Society Annual Meeting

100% of evaluable patients in target dose had no relapse during the four-week follow-up period

Independent objective EEG seizure analysis confirms target dose

Ganaxolone effective regardless of prior AED treatment and across diverse disease etiologies for RSE

KOL call and live webcast on Monday, December 9^th at 7:15am ET

RADNOR, PA, December 7, 2019 (Globe Newswire) – Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (“Marinus” or “Company”), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy, depression and other neuropsychiatric disorders, announced additional data from its open-label, dose-finding Phase 2 study evaluating intravenous (IV) ganaxolone in patients with refractory status epilepticus (RSE). The results were presented at the American Epilepsy Society (AES) annual meeting by Eugene Ramsay, M.D., Director Emeritus, Ochsner Comprehensive Epilepsy Center in New Orleans, and investigator in the study.

“We believe that the expanded data from this Phase 2 study are highly compelling and demonstrate the ability of ganaxolone to rapidly break status, maintain seizure control, and prevent progression to IV anesthetics across a diverse and severe patient population,” said Scott Braunstein, M.D., Chief Executive Officer of Marinus. “These additional data provide important confirmation of our target dose through an independent analysis. Paired with our long-term follow up data that show 100% of patients in the target dose cohort have no status relapse during the 4-week follow up period, we are confident that we have identified an optimized target dose for future studies that balances safety, efficacy and durability of responses. We are on-track for an End of Phase 2 meeting with the FDA in the first quarter of 2020 and look forward to rapidly advancing this promising program to a potentially registration enabling study.”

Key Presentation Highlights:

· Previously announced study results demonstrated that 100% of patients achieved the primary endpoint of preventing progression to IV anesthetics within 24 hours of treatment initiation. Additional long-term data, presented for the first time at AES, demonstrate that all evaluable patients (n=6) in the target dose cohort did not experience status relapse during the four-week follow up period.

· Efficacy and safety were consistent across disease etiologies and both nonconvulsive status epilepticus (NCSE) and convulsive status epilepticus (CSE) patients.

· Baseline patient characteristics showed that in the 17 patients enrolled in the study, 7 had RSE resulting from a vascular condition, 4 cases were caused by tumors, 2 by autoimmune disease and 2 by drug overdose/withdrawal. The underlying cause in one patient was unknown. Seven of the patients had a prior history of epilepsy.

· Patients failed a mean of 2.1 second-line IV AED with all patients failing both levetiracetam and lacosamide. All prior AEDs were given at therapeutically relevant doses, administered within recommended dosing guidelines and mean time since addition of most recent AED was 4 hours.

In addition, an independent central review of seizure EEG data as an objective diagnostic tool demonstrated a clear dose effect with the target dose level providing sustained reductions in seizure burden (greater than 80%) throughout the entire analysis window.

Expanded efficacy study results including 4-week follow up data:

Cohort	No escalation to IV anesthetics within 24 hours from infusion initiation (Primary Endpoint)	Status-free at 24 hours from infusion initiation	No escalation to additional IV AEDs or IV anesthetics for status relapse at any time through the 24-hour follow-up period	No SE Relapse at any time during the 4-week follow up period
Target (713 mg/day; n=8)1	100% (8 of 8)	88% (7 of 8)	100% (8 of 8)	100% (6 of 6)
Medium (650 mg/day; n=4)2	100% (4 of 4)	100% (4 of 4)	75% (3 of 4)	67% (2 of 3)
Low (500 mg/day; n=5)3	100% (5 of 5)	100% (5 of 5)	60% (3 of 5)	50% (1 of 2)

1. One patient in the target dose cohort had status relapse at Day 1, which resolved during the ganaxolone infusion without treatment escalation, one patient discontinued early due to severe sedation on day 1 and one patient died 9 days after ganaxolone discontinuation due to bowel perforation, which was not considered to be drug related.

2. In the medium dose cohort, one patient experienced status relapse at Day 2 during taper and one patient discontinued on day 3 due to severe sedation.

3. In the low dose cohort, two patients escalated to 3^rd line therapy for seizure relapse at Day 3 (one of which died 16 days after ganaxolone discontinuation due to life support withdrawal) and one patient died 22 days after ganaxolone discontinuation due to sepsis. None of the deaths were considered to be drug related.

Dr. Eugene Ramsay said, “The expanded data set presented at AES further bolsters our confidence that ganaxolone has the potential to establish a new treatment paradigm for RSE, a life-threatening condition with no approved treatments. These data build upon the previously reported remarkable efficacy, where all study participants did not need the addition of IV anesthetics. Ganaxolone provided rapid onset of efficacy, the effect of ganaxolone was sustained, and dose specific, with no relapses observed in those patients who received the target dose and who were followed for 4 weeks. Importantly, we also see that ganaxolone is effective across a population representative of the refractory status patients that we commonly see, suggesting that

it can be broadly utilized regardless of the underlying cause of status. These data demonstrate that ganaxolone has the potential to revolutionize the treatment of status.”

Trial Design

The Phase 2 RSE proof-of-concept clinical trial was an open-label, efficacy, safety and PK, dose-finding study conducted at 8 sites in the U.S. The study enrolled 17 medically heterogeneous patients that received an infusion of IV ganaxolone (adjunctive to second line standard of care AED) for up to 96 hours followed by a taper. The three dose groups studied were a low dose (500 mg/day), medium dose (650 mg/day) and target dose (713 mg/day). RSE patients enrolled into the study had failed a mean of 2.1 second line IV AEDs. The primary endpoint for the study was prevention of progression to third line IV anesthetics within the first 24 hours post treatment initiation. Secondary endpoints included safety, tolerability and other efficacy analyses.

KOL Breakfast and Live Webcast

Marinus will host a KOL breakfast meeting and webcast on Monday, December 9^th from 7:15am to 8.30am ET which will feature presentations by Michael A. Rogawski, M.D., Ph.D., University of California, Davis, a key opinion leader in the field of neurosteroids, as well as Joe Hulihan, M.D., Chief Medical Officer of Marinus. Members of the Company’s management team will also present further information on its recently completed Phase 2 trial of ganaxolone in RSE. The breakfast will be held at the Royal Sonesta Harbor Court, 550 Light Street Baltimore, MD and is intended for institutional investors and sell-side analysts. Please RSVP in advance if you plan to attend, as space is limited. The live webcast and replay of the event will be accessible here, and is also available on the Investors page of the Company’s website https://www.marinuspharma.com/investors.

About RSE

Status epilepticus (SE) is a rare epileptic seizure of prolonged duration, lasting more than five minutes for convulsive seizures or 30 minutes for non-convulsive. It is believed to affect approximately 75,000 patients in the U.S. each year.  SE is a true medical emergency that can cause permanent damage to the brain and even death if not quickly brought under control.  SE is first treated with IV benzodiazepines then IV anti-epileptic drugs.  Patients that fail second line treatment with IV AEDs, are considered to be in refractory status epilepticus (RSE). There are currently no indicated treatments for refractory RSE.  The primary treatment goals of clinicians treating SE are; to stop the patient from seizing immediately, assess and resolve the underlying medical condition, and move the patient towards discharge from the hospital as quickly as possible.

About Ganaxolone

Ganaxolone, a positive allosteric modulator of GABA_A, is being developed in three different dose forms (intravenous, capsule and liquid) intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Unlike benzodiazepines, ganaxolone exhibits anti-seizure and anti-anxiety activity via its effects on synaptic and extrasynaptic GABA_A receptors.  Ganaxolone has been studied in more than 1,600 subjects, both pediatric and adult, at therapeutically relevant dose levels and treatment regimens for up to four years. In these studies, ganaxolone was generally safe and well-tolerated. The most commonly reported adverse events were somnolence, dizziness and fatigue.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of ganaxolone, which offers a new mechanism of action, demonstrated efficacy and safety, and convenient dosing to improve the lives of patients suffering from epilepsy and depression. Ganaxolone is a positive allosteric modulator of GABA_A that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant and anti-anxiety effects. Ganaxolone is being developed in IV and oral dose forms intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings.  Marinus is conducting the first ever pivotal studies in children with CDKL5 deficiency disorder and PCDH19-related epilepsy and has recently released top-line data from Phase 2 studies in women with postpartum depression and patients with refractory status epilepticus. For more information visit www.marinuspharma.com. Please follow us on Twitter: @MarinusPharma.

Forward-Looking Statements

To the extent that statements contained in this press release are not descriptions of historical facts regarding Marinus, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “may”, “will”, “expect”, “anticipate”, “estimate”, “intend”, “believe”, and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Examples of forward-looking statements contained in this press release include, among others, statements regarding our interpretation of preclinical studies, development plans for our product candidate, including the development of dose forms, the clinical study testing schedule and milestones, the ability to complete enrollment in our clinical studies, interpretation of scientific basis for ganaxolone use, timing for availability and release of data, the safety, potential efficacy and therapeutic potential of our product candidate and our expectation regarding the sufficiency of our working capital. Forward-looking statements in this release involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the conduct of future clinical studies, the timing of the clinical studies, enrollment in clinical studies, availability of data from ongoing clinical studies, expectations for regulatory approvals, the attainment of clinical study results that will be supportive of regulatory approvals, and other matters, including the development of formulations of ganaxolone, and the availability or potential availability of alternative products or treatments for conditions targeted by the Company that could affect the availability or commercial potential of our drug candidates. Marinus undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see filings Marinus has made with the Securities and Exchange Commission.

CONTACT:

Lisa M. Caperelli

Executive Director, Investor & Strategic Relations

Marinus Pharmaceuticals, Inc.

484-801-4674

lcaperelli@marinuspharma.com

EX-99.2

Exhibit 99.2

NASDAQ: MRNS @ MarinusPharma IV Ganaxolone in Refractory Status Epilepticus (RSE): Phase 2 Clinical Data & Phase 3 Planning December 9, 2019 American Epilepsy Society Annual Meeting

©2019 Marinus Pharmaceuticals. All Rights Reserved. Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding Marinus, they ar e forward - looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Secu rit ies Litigation Reform Act of 1995. Words such as “may”, “will”, “expect”, “anticipate”, “estimate”, “intend”, “believe”, and similar expressions (as w ell as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward - looking statements. Examples of forwar d - looking statements contained in this press release include, among others, statements regarding our interpretation of preclinical studies, develo pme nt plans for our product candidate, including the development of dose forms, the clinical trial testing schedule and milestones, the ability to comple te enrollment in our clinical trials, interpretation of scientific basis for ganaxolone use, timing for availability and release of data, the safety, potential eff ica cy and therapeutic potential of our product , market opportunity for our products, including estimates on patient population, pricing and reimbursement, and our expectation regarding the sufficiency of our working capital. Forward - looking statements in this release involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward - looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the conduct of future clinical tr ials, the timing of the clinical trials, enrollment in clinical trials, availability of data from ongoing clinical trials, expectations for regulatory approva ls, the attainment of clinical trial results that will be supportive of regulatory approvals, and other matters, including the development of formulations of ganaxolone , and the availability or potential availability of alternative products or treatments for conditions targeted by the company that could affect the availability or commercial potential of our drug candidates. Marinus undertakes no obligation to update or revise any forward - looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward - looking statements, as well as risks relating to the business of the Company in general, see Marinus' 10 - Q dated August 8, 2019 and other filings by the company with the U.S. Securities and Exchange Commission. You m ay access these documents for free by visiting EDGAR on the SEC web site at www.sec.gov . 2

©2019 Marinus Pharmaceuticals. All Rights Reserved. Mortality Overall mortality is ~17 - 39% in RSE patients 3,7 Mean RSE duration (in hrs.) between survivors and non - survivors was found to be 88.9 and 120.3 (p=0.002) 3 Hospital stay Patients that achieve SE cessation within 1 or 12 hours (convulsive or non - convulsive SE, respectively) spent significantly less days in the hospital (p<0.001) 5 General Outcomes Mean RSE duration between patients that had a ‘good’ or ‘bad’ outcomes were 7 and 14 days (p=0.003) 4 Refractory Status Epilepticus is a Neurological Emergency 3 1 Betjemann JP & Lowenstein DH 2015 Lancet Neurol 2 Sutter R et al. 2013 Nature Reviews Neurology 3 Sutter R et al. 2013 Epilepsia 4 Madžar D et al. 2016 J. Neurol. 5 Kellinghaus C et al. 2019 Ann. Neurol. 7 Novy et al 2010 6 Hockher SE et al. 2013 JAMA Neurol. Increased duration of SE leads to neuronal damage, pharmacoresistance , and worse outcomes 1,2 IV anesthetics are effective at achieving SE cessation however are associated with significant complications 6 More infections during SE (p<0.0001) Increased hospital stay (29 days vs. 19 days, p=0.0005) ~2.9x increased relative risk for death Increased ICU stay (14 days vs. 5 days, p<0.0001)

©2019 Marinus Pharmaceuticals. All Rights Reserved. Goals of a new treatment for RSE Rapid cessation of SE Maintenance of seizure control over study period Prevent patient progression towards escalation of treatment (IV anesthetics) Goals of a New Therapy for the Treatment of RSE Benzodiazepine Administered Medically induced Coma Established Status Epilepticus (ESE) 1 st line 4 2 nd line IV AED’s 3 rd line IV Anesthetics Super Refractory Status Epilepticus (SRSE) Refractory Status Epilepticus (RSE) ESETT Ganaxolone STATUS (SAGE - 547) Trial

©2019 Marinus Pharmaceuticals. All Rights Reserved. Ganaxolone (GNX) Mechanism of Action • GNX is a synthetic analog of endogenous allopregnanolone and a potent positive allosteric modulator of GABA A - receptors. • GNX targets unique binding sites on GABA A - receptors that are not susceptible to tolerance build up (e.g., benzodiazepines) 5 e.g., GNX • GNX acts on both synaptic and extrasynaptic GABA A - receptors to maximize inhibitory signaling as well as maintain activity when synaptic receptors are down - regulated

©2019 Marinus Pharmaceuticals. All Rights Reserved. Rationale for IV GNX for the Treatment of RSE 6 Ganaxolone has demonstrated a broad range of anticonvulsant and psychotherapeutic responses Benzodiazepines are effective in treating acute seizures but not RSE • Benzodiazepines are positive allosteric modulators of the synaptic (gamma subunit) GABA A receptor • These receptors downregulate with prolonged seizures which explains why SE patients become refractory to benzodiazepines • These receptors also downregulate with chronic benzodiazepine administration Ganaxolone is a positive allosteric modulator of synaptic and extrasynaptic (delta subunit) GABA A receptors • The extrasynaptic receptor does not downregulate with prolonged seizures and explains why RSE patients may remain responsive to ganaxolone

©2019 Marinus Pharmaceuticals. All Rights Reserved. Key Differences in GNX (RSE) Trial and STATUS Trial (SRSE) 7 STATUS in SRSE GNX in RSE Patient Population SRSE: medically more difficult to treat than RSE; seizures less likely to respond than RSE RSE: More likely to respond than SRSE via engagement of GABA A receptors (synaptic and extrasynaptic) Treatment Algorithm On IV anesthetic with goal to wean from IV anesthetics Failed ≥ 1 IV AED. Goal is to prevent escalation to IV anesthetic Primary Endpoint Prevent relapse following IV anesthetic discontinuation Prevent progression to IV anesthetic (Phase 2) Drug Dosing (target plasma level) ~50 - 100 ng/mL ~500 ng/mL

©2019 Marinus Pharmaceuticals. All Rights Reserved. Treatment Period Loading Dose Maintenance Taper Phase 2 RSE Trial Design Diagnosis of convulsive or non - convulsive SE Failed at least one 2 nd line IV AED but had not progressed to 3 rd line IV anesthetics Bolus plus continuous infusion 2 - 4 day infusion 18 hour taper Screening Post - treatment Follow - up 24 hr Weeks 2, 3, 4 8 RSE Patients Cohort Dose of GNX/day N Low 500mg/day 5 Medium 650mg/day 4 Target 713mg/day 8 Evaluate safety, tolerability, efficacy, and pharmacokinetics of IV Ganaxolone in RSE patients Endpoints • Primary: number of patients who do not require escalation of treatment with IV anesthetic within the first 24 hours after ganaxolone i nit iation • Secondary: additional efficacy, safety and tolerability

©2019 Marinus Pharmaceuticals. All Rights Reserved. Baseline Characteristics 9 17 patients enrolled • 8 males, 9 females • Mean age: 57 years old (range: 23 - 88) Types of SE • 5 (29%) CSE, 11 (65%) NCSE, 1 (6%) CSE → NCSE History of Epilepsy • 7 (41%) yes, 10 (59%) no Mean # of failed IV AEDs (including benzodiazepines) • 2.9 (range: 2 - 5) Mean # of failed 2nd - line IV AEDs • 2.1 (range: 1 - 4), all failed LEV or LAC • All prior AED’s were administered within recommended dosing guidelines Patient Dosing Cohort Etiology History of Epilepsy Type of SE Failed Antiseizure Medications Prior to GNX* Dose of Last IV AED Administered Prior to GNX (Recommended Dose) 1 Low Vascular No NCSE LAC , LEV 200mg (200 - 600mg) 2 Low Unknown Yes NCSE fPHT , LEV 1,000mg (1000 - 3000mg) 3 Low Vascular No NCSE LOR, LAC , LEV 600mg (200 - 600mg) 4 Low Vascular No NCSE LOR, LAC , LEV 600mg (200 - 600mg) 5 Low Tumor No CSE LOR, LAC, LEV 2,000mg (1000 - 3000mg) 6 Medium Vascular No NCSE LOR, LAC , LEV 600mg (200 - 600mg) 7 Medium Drug Overdose / Withdrawl Yes CSE LOR, LEV 1,000mg (1000 - 3000mg) 8 Medium Unknown Yes CSE → NCSE LOR, LAC, LEV 1,000mg (1000 - 3000mg) 9 Medium Tumor Yes NCSE LAC, LEV, PHT 200mg (100mg) 10 Target Vascular Yes CSE LOR, LAC , VPA 400mg (200 - 600mg) 11 Target Drug Overdose / Withdrawl No CSE LOR, LAC , LEV 400mg (200 - 600mg) 12 Target Tumor Yes NCSE LOR, LEV, VPA 700mg (1000 - 3000mg) 13 Target Autoimmune No NCSE LOR, LEV 1,000mg (1000 - 3000mg) 14 Target Vascular No NCSE LOR, LAC , LEV, PHT 200mg (200 - 600mg) 15 Target Vascular Yes CSE LOR, LEV 1,000mg (1000 - 3000mg) 16 Target Tumor No NCSE LOR, LAC , LEV 400mg (200 - 600mg) 17 Target Autoimmune No NCSE LOR, fPHT , LAC , LEV, VPA 200mg (200 - 600mg) NCSE: Non - convulsive status epilepticus, CSE: Convulsive status epilepticus, LAC: Lacosamide , LEV: Levetiracetam, LOR: Lorazepam, PHT: Phenytoin, fPHT : Fosphenytoin , VPA: Valproic Acid *Bolded, underlined IV AED’s were the last ones administered prior to GNX

©2019 Marinus Pharmaceuticals. All Rights Reserved. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 0 6 12 18 24 Patient # T i m e P r i o r t o G N X I n i t a t i o n ( h r s ) ( t o p o f e a c h b a r i n d i c a t e s w h e n A S D w a s i n i t i a t e d ) 1st Prior ASD 2nd Prior ASD LAC LEV LOR LAC LEV LAC LAC LOR LOR LOR PHT LAC LAC VPA LEV LOR LOR LAC LAC LEV LEV LOR PHT LOR LOR LEV MDZ PHT LAC LEV LOR LEV LOR LOR LAC LEV fPHT LEV Low Medium Target Preliminary Data – Prior Two Failed Antiseizure Drugs (ASDs) 10 LAC: Lacosamide , LEV: Levetiracetam, LOR: Lorazepam, PHT: Phenytoin, fPHT : Fosphenytoin , VPA: Valproic Acid, MDZ: Midazolam All prior ASD’s were administered at therapeutic levels and within recommended dosing guidelines Two previous ASD’s administered before GNX initiation Immediate previous ASD administered 4 hours (mean) prior to GNX

©2019 Marinus Pharmaceuticals. All Rights Reserved. Ganaxolone Provides Rapid Onset and Durability of Efficacy 11 Cohort No escalation to IV anesthetics within 24 hrs from infusion initiation (Primary Endpoint) Status - free through 24 hrs from infusion initiation No escalation to additional IV AEDs or IV anesthetics for status relapse at any time through 24 hrs after GNX discontinuation No SE Relapse at anytime during the 4 - wk follow up period Target (713 mg/day) (n=8) 100% (8 of 8) 88% (7 of 8) 100% (8 of 8) 100% (6 of 6) (1ET, 1 died) Medium (650 mg/day) (n=4) 100% (4 of 4) 100% (4 of 4) 75% (3 of 4) 67% (2 of 3) (1 ET) Low (500 mg/day) (n=5) 100% (5 of 5) 100% (5 of 5) 60% (3 of 5) 50% (1 of 2) (1 died) ET: Early termination Target dose: One patient had status relapse @ Day 1, which resolved during the ganaxolone infusion without treatment escalati on Medium dose: One patient escalated to additional IV AED @ Day 1 for seizure relapse. One patient experienced status relapse @ Da y 2 (during taper). Low dose: Two patients escalated to 3 rd line therapy for seizure relapse @ Day3 0 10 20 30 200 300 T i m e t o S E C e s s a t i o n ( m i n s ) p e r I n v e s t i g a t o r a s s e s s m e n t SE Cessation Occurred Rapidly in All Dose Groups (median = 5 minutes)

©2019 Marinus Pharmaceuticals. All Rights Reserved. PK/PD Relationship and Rationale for Target Dose 12 0 3 6 9 0 200 400 600 800 1,000 Time (hrs) G N X P l a s m a C o n c e n t r a t i o n ( n g / m L ) Low (model) Low Dose Patient Recurrence of abnormal EEG activity Acute maintenance of GNX plasma concentrations ≥ 500 ng/mL is associated with improved seizure control on EEG 1 2 1 2 3 3

©2019 Marinus Pharmaceuticals. All Rights Reserved. PK/PD Relationship and Rationale for Target Dose 13 Dashed lines are PK models 0 6 12 18 24 0 200 400 600 800 1,000 Time (hrs) G N X P l a s m a C o n c e n t r a t i o n ( n g / m L ) Low 500mg/day Medium 650mg/day Target 713mg/day Seizure Burden Reduction Occurred Rapidly in All Dose Groups Modeled PK Curves for All Dose Groups Target Dose Achieves ≥ 500 ng/mL for ~8 hours Only Target Dose Provided Sustained Reduction (>80%) Throughout Entire Analysis Window -1 -100 -80 -60 -40 -20 0 0 1 2 4 6 8 10 12 14 Time (hrs) % C h a n g e i n E E G S e i z u r e B u r d e n ( s e i z u r e t i m e / t o t a l t i m e p e r i o d ) GNX initiation Target 713mg/day Medium 650mg/day Low 500mg/day

©2019 Marinus Pharmaceuticals. All Rights Reserved. Prevented escalation to IV anesthetics No patients progressed to IV anesthetics during first 24 hours (100% achievement of primary endpoint) Rapid onset of action IV GNX achieved SE cessation at median of 5 minutes (n=15 evaluable) and ~80% seizure burden reduction achieved within 15 minutes Durability Target dose group achieved >80% seizure burden reduction for the entire analysis time (24 hrs ) and no patients experienced SE relapse during the 4 - week follow - up period Safety IV GNX showed an acceptable safety profile in patients with RSE Phase 2 Efficacy and Safety 14

©2019 Marinus Pharmaceuticals. All Rights Reserved. 2 related in 2 patients • 2 severe sedation 13 Related in 7 patients • 6 mild (2 hypotension, 2 somnolence, 1 urinary retention, 1 hypercarbia) • 5 moderate (4 somnolence; 1 hypercarbia) • 2 severe (2 sedation) IV Ganaxolone Safety Summary 15 10 SAEs in 6 patients (also included in AEs) 50 AEs in 16 patients 8 non - related in 4 patients 37 Not - Related in 12 patients • 20 mild • 8 moderate (2 pain; 2 pneumonia, 2 dysphagia, • 1 delirium, 1 hypertension) • 9 severe (respiratory depression, death due to withdrawal of support, sepsis, embolic stoke, perforated bowel, fall, loss of consciousness, multiple fractures, pneumothorax) • 1 Death due to withdrawal of life support – 1 Respiratory depression • 1 Bowel perforation (fatal) • 1 Sepsis (fatal) • 1 Fall – 1 Loss of consciousness – 1 Pneumothorax – 1 Multiple fracture Intubation • 9 patients were not intubated upon enrollment. Of these, 6 remained intubation - free during the entire ganaxolone treatment perio d

©2019 Marinus Pharmaceuticals. All Rights Reserved. Phase 3 Planning 16 Study Design Randomized, placebo - controlled (adjunctive to standard - of - care) clinical trial Target Patient Population RSE patients with similar baseline characteristics (etiology, # of failed IV AED’s, etc.) to the Phase 2 study Dosing: Target dose range but extends GNX exposure ≥ 500 ng/mL from 8 to 12 hours Primary and Key Secondary Endpoints Focuses on clinically - meaningful effects related to rapid onset of action, durability of effect, and prevention of treatment escalation Other Endpoints Target key areas of safety (e.g., % intubated on GNX, time to extubation , etc.) and healthcare utilization metrics (e.g., length of stay, # of days in the ICU, etc.) *Proposed Phase 3 clinical trial elements contingent on future regulatory interactions* Targeting End of Phase 2 meeting with FDA in Q1 - 2020

©2019 Marinus Pharmaceuticals. All Rights Reserved. Cause Defect or mutation of TSC1 and/or TSC2 genes Symptoms Benign tumors, seizures, cognitive impairment, behavioral problems, skin abnormalities Prevalence ~25K patients with refractory epilepsy Treatments Limited approved treatments Mechanistic Rationale GABA A receptor active steroids are altered 1 Tuberous Sclerosis Complex – Rare, Serious Genetic Disorder 17 1 diMichele , et al, J. Neuro Neurosurg Psychiatry , 2003.

©2019 Marinus Pharmaceuticals. All Rights Reserved. PART A PART B Base (4 Weeks) GNX Titration (4 Weeks) GNX Maintenance (8 Weeks) Open - Label Extension (OLE) (24 Weeks) * Available to patients that respond to GNX as defined per protocol* Phase 2 Open - Label Clinical Trial Design in TSC • n = 30 • 4 - 5 U.S. sites • Primary efficacy endpoint: % change in primary seizure frequency Primary seizure types: focal motor seizures without impairment of consciousness or awareness, focal seizures with impairment of consciousness or awareness, focal seizures evolving to bilateral generalized convulsive seizures, and generalized seizures wi th a motor component that are countable 18 Baseline Period Treatment Period OLE Period Screening Visit Baseline Treatment Visit 2 week taper upon GNX discontinuation (if not continuing to Part B)

NASDAQ: MRNS @ MarinusPharma SE & RSE Patient Volume, Pricing & Market Overview Investor Breakfast Meeting AES December 9, 2019

©2019 Marinus Pharmaceuticals. All Rights Reserved. - 10,000 20,000 30,000 40,000 50,000 60,000 70,000 80,000 90,000 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 POPULATION IN NUMBERS (N) YEAR Incident Population of Status (SE) in Seven Major Markets United States United Kingdom Germany Italy France Spain Japan Status Epilepticus (SE) Patient Population* 20 SE Patient Population Summary - 2019 • U.S. is the single largest market (~72k pts.) • EU5 is slightly larger than U.S. market (~84k pts.) • Additional SE patients are present in EU Ex - EU5 • Japan has more patients than any EU country (~32K pts) • All pt. # would qualify for orphan status in each country • Patient growth projected to be relatively flat (<1% p.a.) *Refractory Status Epilepticus: Disease Coverage, Pipeline and Market Analysis, Market & Epidemiology Forecast - 2029 – Quintana R esearch There are approx. 188K total Status Epilepticus (SE) patients distributed across the 7 major markets - 10,000 20,000 30,000 40,000 50,000 60,000 70,000 80,000 90,000 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 POPULATION IN NUMBERS (N) YEAR Incident Population of Status (SE) in Seven Major Markets United States United Kingdom Germany Italy France Spain Japan 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 10,000 20,000 30,000 40,000 50,000 60,000 70,000 80,000 90,000

©2019 Marinus Pharmaceuticals. All Rights Reserved. - 5,000 10,000 15,000 20,000 25,000 30,000 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 POPULATION IN NUMBERS (N) YEAR Incident Population of Refractory Status (RSE) in Seven Major Markets United States United Kingdom Germany Italy France Spain Japan - 10,000 20,000 30,000 40,000 50,000 60,000 70,000 80,000 90,000 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 POPULATION IN NUMBERS (N) YEAR Incident Population of Status (SE) in Seven Major Markets United States United Kingdom Germany Italy France Spain Japan Refractory Status Epilepticus (RSE) Patient Population RSE Patient Population Summary • RSE estimated to be 30% - 50% of total SE patients • US is the single largest market (~23k - 36k pts.) • EU5 is larger than US market (~31k - 42k pts.) • Additional RSE pts. In EU Ex - EU5 • Japan roughly equal to Germany (~10k - 15k pts.) • All patient volumes would qualify for orphan status • Patient growth projected to be flat (<1% p.a.) *Refractory Status Epilepticus: Disease Coverage, Pipeline and Market Analysis, Market & Epidemiology Forecast - 2029 – Quintana R esearch 21 There are approx. 64K total Refractory Status Epilepticus (RSE) patients distributed across the 7 major markets 10,000 5,000 15,000 20,000 25,000 30,000 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029

©2019 Marinus Pharmaceuticals. All Rights Reserved. SE represents a high degree of unmet clinical need and substantial commercial opportunity SE Treatment Dynamics & Unmet Need SE treatment response rates of 50% - 70% with SOC (per med literature, KOLs, MR) • 30% - 50% of SE patient will not respond to 1 st line (IV benzo) or 2 nd line (IV AED) treatments Refractory SE patients commonly are placed on IV anesthetics to control/stop seizures • Requires ICU admission and is associated with unacceptably high rates or mortality and morbidity Clinicians are dissatisfied with current SE SOC and seeking therapeutic alternatives to: • Stop seizures as quickly as possible to protect against neuronal damage • Maintain seizure cessation to address and stabilize underlying medical etiology • Mitigate need to escalate intensity of treatment/care with attendant burdens No currently indicated RSE treatments with no treatments in development other than GNX • RSE represents clinical “white space” for GNX market entry and product adoption • Opportunity to establish new treatment paradigms/algorithms with GNX entry to treatment armamentarium • No meaningful competitive presence in market to slow/block GNX adoption 22

©2019 Marinus Pharmaceuticals. All Rights Reserved. GNX has the potential to move up in the treatment continuum for utilization in some segment of the SE population SE Market Expansion Potential Key drivers for the potential use of GNX in SE: • Potential to conduct Phase IV clinical studies to demonstrate safety and efficacy of GNX in SE post RSE approval • Pharmacoeconomic studies could support GNX use in more severe/complicated SE patients • Rapid onset of action could be attractive to clinicians to displace some use of 1st and 2nd line agents in SE to neuro - protect • Positive clinician experience with GNX in RSE could support expanded use into SE over time • GNX will have maximum voice due to lack of any currently or expected branded treatments • Availability of GNX could precipitate establishment of new treatment protocols and algorithms SE Market represents an additional 36K - 50K patients beyond RSE • Morbidity and mortality risk high in these patients with current treatments • Each 1,000 incremental SE patient is equivalent to ~$35MM - $50MM of incremental revenue vs. RSE forecast 23

©2019 Marinus Pharmaceuticals. All Rights Reserved. Pharmacy Directors, NEUROs, and Payers recommended a $25,000 - $50,000 range for a novel RSE agent GNX Pricing Payer Primary Market Research – U.S. 24 Pricing a novel RSE agent below the current DRG ensures that hospitals will be reimbursed without appealing to payers for disease - specific specialty drug carve - outs RSE treatment is restricted to the inpatient setting: reimbursement is determined by the current DRG The DRG to treat RSE is set at $45,000 - $50,000 for Medicare patients Most commercial plans set their RSE “Case Rate” to approximate the DRG All respondents - including payers - recommend pricing a novel RSE agent below the DRG and current hospital costs Current Hospital Costs: $30,000 - $75,000 Required Savings: 15% - 30% RSE treatment pricing: $25,000 - $50,000 We recommend additional research to identify optimal pricing strategies for a novel RSE product

©2019 Marinus Pharmaceuticals. All Rights Reserved. Shorten hospital stay Bypass ICU Reduce adverse events • Rapid and sustained seizure control • No recovery/rehab from sedation • Bolus delivery suitable for the ER • No need for intubation • No intensive cardiovascular monitoring • Avoid frequent complications associated with intubation/ventilator/ICU GNX SE/RSE Reimbursement Dynamics 25 FEW HOURS 2 DAYS 2 DAYS $10,000 $3,000 $2,000 Pharmaco - economic benefit RSE clinical benefits Clinicians and payers are both seeking to reduce escalation of care and hospital LOS to improve patient outcomes Pharm Ds and NEUROs : a novel RSE treatment that reduces hospital costs by 20% would be quickly added to the hospital formulary “If you can save $15,000 and offer other benefits then it's a no - brainer for the P&T committee.” Pharmacy Director POTENTIAL RSE HOSPITAL STAY (Given availability of novel agent) COST/DAY ER Step - down Unit Hospital Floor

©2019 Marinus Pharmaceuticals. All Rights Reserved. SE/RSE DRG Summary* DRG Code Description Mean Covered Charges DRG - 100 Seizure with MCC** $59,800 DRG - 101 Seizure w/or MCC** $30,890 Unweighted Average $45,345 *Publicly available data from CMS for SE – needs to be further refined through additional data analysis and primary market resea rch **MCC = major complication or comorbidity DRG mean charges for SE with complication or comorbidities approached $60K/case in FY2017 *Source: https://www.cms.gov/Research - Statistics - Data - and - Systems/Statistics - Trends - and - Reports/Medicare - Provider - Charge - Data/In patient2017 Primary MR with payers has indicated that the DRG would be the appropriate reference point for establishing GNX price vs. cost of current SOC drugs (@ ~20% discount) 26

©2019 Marinus Pharmaceuticals. All Rights Reserved. RSE Market By Territory: $1B+ opportunity $- $200.00 $400.00 $600.00 $800.00 $1,000.00 $1,200.00 Low Price High Price RSE Market Opportunity By Region US EU5 Japan RSE market is valued between $1B - $2B at premium prices in 2019 based on projected pricing range in each territory Low Case Price • US - $25k • EU - $10K • Japan - $15K 27 High Case Price • US - $50k • EU - $20K • Japan - $30K

©2019 Marinus Pharmaceuticals. All Rights Reserved. US RSE Market Size & Value 28 Refractory Status Epilepticus - Disease Coverage, Pipeline and Market Analysis, Market & Epidemiology Forecast - 2029 – Quintana Res earch RSE represents a substantial peak revenue opportunity for GNX ranging between ~$350MM - $700MM annually in RSE only based on conservative assumptions U.S. RSE Market Valuation Sensitivity Analysis Price @ $10,000 $20,000 $25,000 $30,000 $40,000 $50,000 United States RSE Market ($MM) $227 $453 $566 $680 $906 $1,133 GNX Market Penetration @ 60% Share ($MM) $136 $272 $340 $408 $544 680 21,500 22,000 22,500 23,000 23,500 24,000 24,500 25,000 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 POPULATION IN NUMBERS (N) YEAR Incident Population of Refractory Status Epilepticus (RSE) by Country US - 10,000 20,000 30,000 40,000 50,000 60,000 70,000 80,000 90,000 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 POPULATION IN NUMBERS (N) YEAR Incident Population of Status (SE) in Seven Major Markets United States United Kingdom Germany Italy France Spain Japan 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 - 10,000 20,000 30,000 40,000 50,000 60,000 70,000 80,000 90,000 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 POPULATION IN NUMBERS (N) YEAR Incident Population of Status (SE) in Seven Major Markets United States United Kingdom Germany Italy France Spain Japan 21,500 22,000 22,500 23,000 23,500 24,000 24,500 25,000

EX-99.3

Exhibit 99.3

Marinus Announces Ganaxolone Orphan Epilepsy Program Updates Including Planned Clinical Program in Tuberous Sclerosis Complex

Initiation of Phase 2 trial evaluating ganaxolone in tuberous sclerosis complex planned for 1H 2020

European Medicines Agency Orphan Drug Designation granted for ganaxolone for the treatment of CDKL5 deficiency disorder

CDKL5 deficiency disorder pivotal Phase 3 trial on-track for data Q3 2020 with strong ongoing enrollment

RADNOR, PA, December 9, 2019 (Globe Newswire) – Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (“Marinus” or “Company”), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and other neuropsychiatric disorders, today announced clinical and regulatory updates for its orphan seizure programs in tuberous sclerosis complex (TSC), CDKL5 deficiency disorder (CDD) and PCDH19-related epilepsy (PCDH19-RE).

Tuberous Sclerosis Complex Program

“The decision to expand our epilepsy program in TSC was strategically informed by the discovery of a new potential epilepsy biomarker, Allo-S, in our Phase 2 study in PCDH19-related epilepsy,” said Scott Braunstein, M.D., Chief Executive Officer of Marinus. “This led us to additional analyses that identified TSC as another rare genetic disorder that may be similarly impacted by Allo-S levels. We look forward to initiating a Phase 2 trial in the first half of 2020 to provide a potential targeted treatment option for these patients with limited approved therapies.”

Marinus intends to initiate a Phase 2, open label study to evaluate the safety and tolerability of adjunctive ganaxolone treatment in patients with seizures associated with TSC. Patient stratification from the Company’s PCDH19-related epilepsy Phase 2 trial identified a subpopulation of patients with improved ganaxolone responses, those with low levels of allopregnanolone-sulfate (Allo-S). Based on these data, the Company performed a biomarker analysis to identify other rare genetic epilepsies that may benefit from the GABA_A-receptor modulatory effects of ganaxolone and today announced TSC as the next planned orphan epilepsy program to study the effect of ganaxolone on seizures as well as the expanded utility of a potential biomarker.

The planned Phase 2 study will be conducted at approximately 4-6 sites in the United States and enroll approximately 20-40 patients ages 2 to 65. Patients will undergo a 4-week baseline period followed by a 12-week treatment period. The primary endpoint for the study is percent change in 28-day primary seizure frequency through the end of the 12-week treatment period relative to the 4-week baseline period.

CDKL5 Deficiency Disorder (CDD) Program

The European Medicines Agency (EMA) has granted orphan drug designation for ganaxolone for the treatment of CDD. EMA orphan designation status is assigned to medicines intended to treat rare conditions and allows recipient companies to benefit from incentives offered by the European Union to develop medicines for the treatment, prevention or diagnosis of a life-threatening or chronically debilitating rare disease.

Dr. Braunstein continued, “Receiving Orphan Drug Designation for our CDD program from the EMA is an important regulatory milestone as we advance ganaxolone through our pivotal Phase 3 Marigold study. We are proud of our continued progress and execution, with strong trial enrollment, and look forward to sharing topline data in Q3 2020.”

Marinus is currently in the final stages of recruiting for the Marigold Study, its pivotal Phase 3 study evaluating the use of oral ganaxolone in children and young adults with CDD, a refractory form of pediatric epilepsy with no currently approved treatments. The global, double-blind, placebo-controlled, pivotal study will enroll up to 100 patients between the ages of 2 and 21 with a confirmed disease-related CDKL5 gene variant. Enrollment in the study continues to progress as planned and the Company remains on-track to report top-line data in Q3 2020.

PCDH19-related Epilepsy (PCDH19-RE) Program

International site initiation and enrollment is continuing in the Violet Study, a single pivotal Phase 3 study evaluating oral ganaxolone in children with PCDH19-RE. The study will enroll up to 70 patients between the ages of 1 and 17 with a confirmed PCDH19 mutation. Patients are stratified into biomarker positive and negative groups, which could potentially provide the epilepsy community with the first diagnostic blood test that predicts the likelihood of a treatment response. The Company remains on-track to report top-line data in 2021.

About Tuberous Sclerosis Complex

Tuberous sclerosis complex (TSC) is a rare genetic disorder that affects many organs and causes non-malignant tumors in the brain, skin, kidney, heart, eyes, and lungs. The condition is caused by inherited mutations in either the TSC1 gene or the TSC2 gene. TSC occurs with a frequency of 1:6,000 and a mutation is found in 85% of patients. While the disease phenotype can be extremely variable, neurologic manifestations such as epilepsy can be seen in up to 90% of TSC patients. TSC is a leading cause of genetic epilepsy, often occurring in the first year of life as either focal seizures or infantile spasms.  There are currently limited approved treatments for TSC.

About CDKL5 Deficiency Disorder

CDKL5 deficiency disorder (CDD) is a serious and rare genetic disorder that is caused by a mutation of the cyclin-dependent kinase-like 5 (CDKL5) gene, located on the X chromosome. CDD is characterized by early-onset, difficult-to-control seizures and severe neuro-developmental impairment. Most children affected by CDD cannot walk, talk, or feed themselves, and many are confined to wheelchairs, dependent on others for everything. Currently, there are no approved therapies for CDD.

About Ganaxolone

Ganaxolone, a positive allosteric modulator of GABA_A receptors, is being developed in an intravenous and oral formulation intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Unlike benzodiazepines, ganaxolone exhibits anti-seizure and anti-anxiety activity via its effects on synaptic and extrasynaptic GABA_A receptors.  Ganaxolone has been studied in more than 1,600 subjects, both pediatric and adult, at therapeutically relevant dose levels and treatment regimens for up to four years. In these studies, ganaxolone was generally safe and well-tolerated. The most commonly reported adverse events were somnolence, dizziness and fatigue.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of ganaxolone, which offers a new mechanism of action, demonstrated efficacy and safety, and convenient dosing to improve the lives of patients suffering from epilepsy and depression. Ganaxolone is a positive allosteric modulator of GABA_A that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant and anti-anxiety effects. Ganaxolone is being developed in IV and oral dose forms intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings.  Marinus is conducting the first ever pivotal studies in children with CDKL5 deficiency disorder and PCDH19-related epilepsy and has recently released top-line data from Phase 2 studies in women with postpartum depression and patients with refractory status epilepticus. For more information visit www.marinuspharma.com. Please follow us on Twitter: @MarinusPharma.

Forward-Looking Statements

To the extent that statements contained in this press release are not descriptions of historical facts regarding Marinus, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “may”, “will”, “expect”, “anticipate”, “estimate”, “intend”, “believe”, and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Examples of forward-looking statements contained in this press release include, among others, statements regarding our interpretation of preclinical studies, development plans for our product candidate, including the development of dose forms, the clinical study testing schedule and milestones, the ability to complete enrollment in our clinical studies, interpretation of scientific basis for ganaxolone use, timing for availability and release of data, the safety, potential efficacy and therapeutic potential of our product candidate and our expectation regarding the sufficiency of our working capital. Forward-looking statements in this release involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the conduct of future clinical studies, the timing of the clinical studies, enrollment in clinical studies, availability of data from ongoing clinical studies, expectations for regulatory approvals, the attainment of clinical study results that will be supportive of regulatory approvals, and other matters, including the development of formulations of ganaxolone, and the availability or potential availability of alternative products or treatments for conditions targeted by the Company that could affect the availability or commercial potential of our drug candidates. Marinus undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see filings Marinus has made with the Securities and Exchange Commission.

CONTACT: 

Lisa M. Caperelli

Executive Director, Investor & Strategic Relations

Marinus Pharmaceuticals, Inc.

484-801-4674

lcaperelli@marinuspharma.com